24.00

2.13% 0.50

Tourmaline Bio Inc (TRML)

Overview News Price History Financials Discussions Forecast

Tourmaline Bio Inc stock is traded at $24.00, with a volume of 151.77K. It is up +2.13% in the last 24 hours and down -15.07% over the past month. Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.

Previous Close:

$23.50

Open:

$23.5

24h Volume:

151.77K

Relative Volume:

0.70

Market Cap:

$617.47M

Revenue:

Net Income/Loss:

$11.77M

P/E Ratio:

-155.14

EPS:

-0.1547

Net Cash Flow:

$-19.23M

1W Performance:

-8.61%

1M Performance:

-15.07%

6M Performance:

+64.84%

1Y Performance:

+35.98%

1-Day Range:

$23.25

$24.55

1-Week Range:

$23.25

$27.51

52-Week Range:

$12.12

$48.31

Tourmaline Bio Inc Stock (TRML) Company Profile

Name

Tourmaline Bio Inc

Sector

Healthcare (1193)

Industry

Biotechnology (683)

Phone

646-481-9832

Address

27 WEST 24TH STREET, NEW YORK

Employee

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

TRML's Discussions on Twitter

Compare TRML with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TRML	24.00	617.47M	0	11.77M	-19.23M	-0.1547
VRTX	451.23	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	743.35	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	591.82	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.79	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.14	24.49B	3.30B	-501.07M	1.03B	11.54

Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-15-23	Initiated	Jefferies	Buy
Dec-04-23	Resumed	H.C. Wainwright	Buy
Nov-17-23	Initiated	Truist	Buy
Oct-31-23	Initiated	Guggenheim	Buy
Oct-25-23	Initiated	Piper Sandler	Overweight
Oct-20-22	Initiated	H.C. Wainwright	Buy
Jul-05-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight

View All

Tourmaline Bio Inc Stock (TRML) Latest News

Nov 18, 2024

Prevent Blindness Declares Fifth Annual Thyroid Eye Disease Awareness Week as Nov. 18-24, 2024 - InvisionMag

Nov 18, 2024

Nov 17, 2024

This Week in Ophthalmology: Week of November 11, 2024 - Ophthalmology Times

Nov 17, 2024

Nov 15, 2024

Blue Owl Capital Holdings LP Adjusts Stake in Tourmaline Bio Inc - GuruFocus.com

Nov 15, 2024

HC Wainwright Reduces Earnings Estimates for Tourmaline Bio - Defense World

Nov 15, 2024

Nov 14, 2024

HC Wainwright Lowers Earnings Estimates for Tourmaline Bio - MarketBeat

Nov 14, 2024

Tourmaline Bio Sets Key Investor Day with Focus on Pacibekitug Development | TRML Stock News - StockTitan

Nov 14, 2024

Alternus Clean Energy Inc (NASDAQ:ALCE) Sees Significant Decrease in Short Interest - Defense World

Nov 14, 2024

Alchemy Investments Acquisition Corp 1 (NASDAQ:ALCY) Short Interest Update - Defense World

Nov 14, 2024

Short Interest in Alchemy Investments Acquisition Corp 1 (NASDAQ:ALCYW) Decreases By 97.6% - Defense World

Nov 14, 2024

Greenlane Renewables (OTCMKTS:GRNWF) Trading 21.2% Higher – Here’s What Happened - Defense World

Nov 14, 2024

Nov 12, 2024

Tourmaline Bio ATM - SVB Leerink

Nov 12, 2024

Varonis Systems, Inc. (NASDAQ:VRNS) Given Average Rating of “Moderate Buy” by Analysts - Defense World

Nov 12, 2024

Nov 11, 2024

Tourmaline Bio, Inc. Reports Third Quarter Financial Results - TipRanks

Nov 11, 2024

Tourmaline Bio (NASDAQ:TRML) Price Target Raised to $49.00 at HC Wainwright - MarketBeat

Nov 11, 2024

Nov 07, 2024